Sanfilippo F
Transplantation Laboratory, Duke University Medical Center, Durham, North Carolina.
Clin Lab Med. 1991 Sep;11(3):537-50.
The major histocompatibility complex (MHC) initially was identified by its strong association with the outcome of transplanted tissues. As in other species, disparity for MHC antigens in humans (especially HLA-A, B, DR) is a good predictor of allograft rejection. Although new immunosuppressive agents have improved graft survival in clinical transplantation, they have not obviated the benefits of avoiding mismatched HLA antigens or incompatible ABO blood group antigens. This article examines the role of HLA and ABO antigens in graft rejection from the perspective of both immunologic mechanisms and clinical outcome.
主要组织相容性复合体（MHC）最初是因其与移植组织的转归密切相关而被识别出来的。与其他物种一样，人类MHC抗原的差异（尤其是HLA - A、B、DR）是同种异体移植排斥反应的良好预测指标。尽管新型免疫抑制剂提高了临床移植中移植物的存活率，但它们并未消除避免HLA抗原错配或ABO血型抗原不相容所带来的益处。本文从免疫机制和临床结果两个角度探讨了HLA和ABO抗原在移植排斥反应中的作用。
